Suchergebnisse - "Ye Li"

PubPharm (7)

1

Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma

enthalten in: Acta pharmacologica Sinica | 2023

von Zhang, L. | Li, X. | Shi, X. | +10

2

The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth

enthalten in: Acta pharmacologica Sinica | 2022

von Xu, F. | Sun, H. | Fang, R. | +10

3

Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer

enthalten in: Acta pharmacologica Sinica | 2019

von Liu, B. | Wang, T. | Li, L. | +9

4

The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways

enthalten in: Acta pharmacologica Sinica | 2018

von Li, H. | Wang, Z. | Jiang, M. | +9

5

MiR-506 suppresses proliferation of hepatoma cells through targeting YAP mRNA 3'UTR

enthalten in: Acta pharmacologica Sinica | 2014

von Wang, Y. | Cui, M. | Sun, B. | +3

6

Promotion of cell proliferation by HBXIP via upregulation of human telomerase reverse transcriptase in human mesenchymal stem cells

enthalten in: Acta pharmacologica Sinica | 2008

von Wang, F. | Sha, L. | Ye, L. | +1

7

Involvement of hepatitis B X-interacting protein (HBXIP) in proliferation regulation of cells

enthalten in: Acta pharmacologica Sinica | 2007

von Wang, F. | Sha, L. | Zhang, W. | +5

1
[1]